AI Engines For more Details: Perplexity Kagi Labs You
Anxiety and Stress Reduction: Magnolia bark contains bioactive compounds such as honokiol and magnolol, which have been studied for their anxiolytic (anti-anxiety) and sedative properties. Magnolia bark extract may help reduce feelings of anxiety, stress, and tension by modulating neurotransmitter activity in the brain.
Sleep Improvement: Due to its calming and sedative effects, magnolia bark extract may help improve sleep quality and duration. It may help alleviate insomnia, promote relaxation, and induce feelings of calmness, making it beneficial for individuals with sleep disturbances or insomnia.
Anti-inflammatory Effects: Magnolia bark contains compounds with anti-inflammatory properties, which may help reduce inflammation and alleviate symptoms of inflammatory conditions such as arthritis, rheumatism, and inflammatory bowel disease (IBD). Magnolia bark extract may help inhibit the production of pro-inflammatory cytokines and enzymes involved in the inflammatory process.
Antioxidant Protection: Magnolia bark is rich in antioxidants, which help neutralize free radicals and protect cells from oxidative damage. Antioxidants may help reduce the risk of chronic diseases such as cardiovascular disease, cancer, and neurodegenerative disorders.
Digestive Health: In TCM, magnolia bark has been used to support digestive health and alleviate symptoms of indigestion, bloating, and abdominal discomfort. It may help regulate gastrointestinal motility, reduce gastric acid secretion, and relieve spasms in the digestive tract.
Weight Management: Some research suggests that magnolia bark extract may help support weight management by reducing appetite, increasing metabolism, and promoting fat breakdown. It may help inhibit the activity of enzymes involved in fat synthesis and storage, making it potentially beneficial for individuals seeking to lose weight.
Oral Health: Magnolia bark extract has antimicrobial and anti-inflammatory properties, which may help promote oral health and prevent dental problems such as cavities, gum disease, and bad breath. It may help inhibit the growth of oral bacteria and reduce inflammation in the gums.
Rank | Probiotic | Impact |
---|---|---|
species | Streptococcus thermophilus | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Allergy to milk products | 0.8 | -0.8 | |
Ankylosing spondylitis | 0.5 | 0.5 | |
Anorexia Nervosa | 0.8 | 0.8 | |
Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
Atrial fibrillation | 0.7 | 0.7 | |
Autism | 0.5 | 0.5 | 0 |
Barrett esophagus cancer | 0.5 | -0.5 | |
Brain Trauma | 0.3 | -0.3 | |
Carcinoma | 0.5 | 0.5 | |
Celiac Disease | 0.5 | 0.5 | 0 |
Cerebral Palsy | 0.5 | 0.5 | |
Chronic Fatigue Syndrome | 0.7 | 0.5 | 0.4 |
Chronic Obstructive Pulmonary Disease (COPD) | 1 | 1 | |
Chronic Urticaria (Hives) | 0.8 | 0.8 | |
Coagulation / Micro clot triggering bacteria | 0.8 | 1.3 | -0.63 |
Colorectal Cancer | 0.3 | 0.3 | |
COVID-19 | 1.8 | 0.7 | 1.57 |
Crohn's Disease | 0.3 | 0.2 | 0.5 |
deep vein thrombosis | 0.2 | 1.3 | -5.5 |
Depression | 1.3 | 0.8 | 0.63 |
Dermatomyositis | 0.5 | 0.5 | |
Eczema | 0.7 | -0.7 | |
Endometriosis | 0.5 | 0.5 | |
Epilepsy | 0.5 | 0.5 | |
Functional constipation / chronic idiopathic constipation | 0.2 | 0.2 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.5 | -1.5 |
Glioblastoma | 0.5 | -0.5 | |
Halitosis | 0.5 | -0.5 | |
Hidradenitis Suppurativa | 0.5 | 0.5 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.2 | 0.2 | |
hyperglycemia | 0.2 | 0.2 | |
hypersomnia | 0.2 | 0.2 | 0 |
hypertension (High Blood Pressure | 0.7 | 0.7 | 0 |
Inflammatory Bowel Disease | 0.8 | 0.8 | |
Insomnia | 0.5 | 0.5 | |
Liver Cirrhosis | 0.7 | 0.7 | 0 |
Long COVID | 1.3 | 1.3 | |
Low bone mineral density | 0.2 | 0.2 | |
ME/CFS with IBS | 0.5 | 0.5 | |
ME/CFS without IBS | 0.5 | 0.5 | |
Metabolic Syndrome | 0.7 | 0.7 | 0 |
Mood Disorders | 1.5 | 0.8 | 0.88 |
multiple chemical sensitivity [MCS] | 0.8 | 0.8 | |
Multiple Sclerosis | 1 | 0.5 | 1 |
Multiple system atrophy (MSA) | 0.2 | 0.2 | |
Neuropathy (all types) | 0.5 | 0.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1 | 1 | |
Obesity | 0.5 | 0.2 | 1.5 |
obsessive-compulsive disorder | 0.5 | 0.5 | |
Osteoarthritis | 0.5 | 0.5 | |
pancreatic cancer | 0.5 | 0.5 | |
Parkinson's Disease | 0.7 | 1 | -0.43 |
Polycystic ovary syndrome | 0.2 | 0.2 | |
Psoriasis | 0.8 | 0.8 | |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.8 | 0.7 | 0.14 |
Schizophrenia | 0.2 | 0.2 | |
Sjögren syndrome | 0.5 | 0.5 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.5 | |
Systemic Lupus Erythematosus | 0.8 | 0.8 | |
Tic Disorder | 0.2 | -0.2 | |
Type 1 Diabetes | 0.5 | -0.5 | |
Type 2 Diabetes | 0.7 | 0.5 | 0.4 |
Ulcerative colitis | 0.9 | 0.9 | |
Unhealthy Ageing | 0.5 | 0.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.